deltatrials
Completed PHASE4 NCT00063609

The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

The Effect of Zoledronic Acid Compared to Placebo on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy

Sponsor: Novartis Pharmaceuticals

Conditions Prostate Cancer
Interventions zoledronic acid
Updated 5 times since 2017 Last updated: Sep 11, 2017 Started: Apr 30, 2003 Completion: Apr 30, 2005

This PHASE4 trial investigates Prostate Cancer and is currently completed. Novartis Pharmaceuticals leads this study, which shows 5 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE4

    First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States, Anaheim, United States, Anchorage, United States, Birmingham, United States, Cincinnati, United States, Columbus, United States, Daytona Beach, United States, Des Moines, United States, Eugene, United States, Evansville, United States and 31 more location s